BA
CADX

BlackRock Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

BlackRock Advisors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-57,685
Closed -$522K – 3668
2013
Q4 		$522K Buy
57,685
+19,151
+50% +$138K ﹤0.01% 2012
2013
Q3 		$243K Buy
38,534
+1,424
+4% +$9.05K ﹤0.01% 2424
2013
Q2 		$253K Buy
+37,110
New +$259K ﹤0.01% 2328

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's CADX Position: Q1 2014 in Review

BlackRock Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 57,685 shares — an estimated $522K sold.

BlackRock Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $522K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • BlackRock Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • BlackRock Advisors sold 57,685 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $522K.
  • BlackRock Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • BlackRock Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $522K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on BlackRock Advisors's 13F filing for Q1 2014, filed 2 May 2014.